Gene therapy of gynaecological diseases

被引:16
作者
Kanerva, Anna
Raki, Mari
Hemminki, Akseli
机构
[1] Univ Helsinki, Transplantat Lab, Canc Gene Therapy Grp, Mol Canc Biol Program, FIN-00290 Helsinki, Finland
[2] Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, FIN-00014 Helsinki, Finland
[3] Univ Helsinki, Cent Hosp, Lab Transplantat Pathol, HUSLAB, FIN-00014 Helsinki, Finland
[4] Univ Helsinki, Cent Hosp, Dept Oncol, FIN-00014 Helsinki, Finland
[5] Biomedicum, Haartman Inst, FIN-00014 Helsinki, Finland
基金
芬兰科学院;
关键词
cervical cancer; gene therapy; gene transfer; gynaecological disease; ovarian cancer; virotherapy;
D O I
10.1517/14712598.7.9.1347
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Gene therapy represents a potentially useful approach for the treatment of diseases refractory to conventional therapies. Various preclinical and clinical strategies have been explored for treatment of gynaecological diseases. Given the most severe unmet clinical need, much of the work has been performed with gynaecological cancers and ovarian cancer in particular. Although the safety of many treatment strategies has been demonstrated in early phase clinical trials, efficacy has been mostly limited heretofore. Major challenges include improving the vectors used with the aim of more effective and selective delivery. In addition, effective penetration into and spreading within advanced and complex tumour masses and metastases remains challenging. This review focuses on existing and developmental gene transfer applications for gynaecological diseases.
引用
收藏
页码:1347 / 1361
页数:15
相关论文
共 131 条
[1]   Gene therapy of uterine leiomyomas: Adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice [J].
Al-Hendy, A ;
Lee, EJ ;
Wang, HQ ;
Copland, JA .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2004, 191 (05) :1621-1631
[2]  
Alvarez RD, 2000, CLIN CANCER RES, V6, P3081
[3]   Adenoviral-mediated suicide gene therapy for ovarian cancer [J].
Alvarez, RD ;
Gomez-Navarro, J ;
Wang, MH ;
Barnes, MN ;
Strong, TV ;
Arani, RB ;
Arafat, W ;
Hughes, JV ;
Siegal, GP ;
Curiel, DT .
MOLECULAR THERAPY, 2000, 2 (05) :524-530
[4]   Alteration of maternal Hoxa10 expression by in vivo gene transfection affects implantation [J].
Bagot, CN ;
Troy, PJ ;
Taylor, HS .
GENE THERAPY, 2000, 7 (16) :1378-1384
[5]   Human papillomavirus E6E7-mediated adenovirus cell killing:: Selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes [J].
Balagué, C ;
Noya, F ;
Alemany, R ;
Chow, LT ;
Curiel, DT .
JOURNAL OF VIROLOGY, 2001, 75 (16) :7602-7611
[6]   Targeted gene therapy of ovarian cancer using an ovarian-specific promoter [J].
Bao, RD ;
Selvakumaran, M ;
Hamilton, TC .
GYNECOLOGIC ONCOLOGY, 2002, 84 (02) :228-234
[7]   Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma [J].
Barker, SD ;
Dmitriev, IP ;
Nettelbeck, DM ;
Liu, B ;
Rivera, AA ;
Alvarez, RD ;
Curiel, DT ;
Hemminki, A .
GENE THERAPY, 2003, 10 (14) :1198-1204
[8]   The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy [J].
Barker, SD ;
Coolidge, CJ ;
Kanerva, A ;
Hakkarainen, T ;
Yamamoto, M ;
Liu, B ;
Rivera, AA ;
Bhoola, SM ;
Barnes, MN ;
Alvarez, RD ;
Curiel, DT ;
Hemminki, A .
JOURNAL OF GENE MEDICINE, 2003, 5 (04) :300-310
[9]   Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells [J].
Bauerschmitz, Gerd J. ;
Guse, Kilian ;
Kanerva, Anna ;
Menzel, Artur ;
Herrmann, Isabell ;
Desmond, Renee A. ;
Yamamoto, Masato ;
Nettelbeck, Dirk M. ;
Hakkarainen, Tanja ;
Dall, Peter ;
Curiel, David T. ;
Hemminki, Akseli .
MOLECULAR THERAPY, 2006, 14 (02) :164-174
[10]  
Bauerschmitz GJ, 2002, CANCER RES, V62, P1266